| Literature DB >> 24917938 |
Frank Zerbib1, Daniel Sifrim2, Radu Tutuian3, Stephen Attwood4, Lars Lundell5.
Abstract
Approximately 30-40% of patients taking proton pump inhibitors (PPIs) for presumed gastro-oesophageal reflux (GOR) symptoms do not achieve adequate symptom control, especially when no oesophageal mucosal breaks are present at endoscopy and when extra-oesophageal symptoms are concerned. After failure of optimization of medical therapy, a careful work up is mandatory that aims at determining whether symptoms are related to GOR or not. Most patients with refractory symptoms do not have GOR-related symptoms. Some may have symptoms related to weakly acidic reflux and/or oesophageal hypersensitivity. Baclofen is currently the only antireflux compound available as add-on therapy to PPIs, but its poor tolerability limits its use in clinical practice. There is room for pain modulators in patients with hypersensitive oesophagus and functional heartburn. Antireflux surgery is a suitable option in patients responding to medical therapy who want to avoid taking medication or if persisting symptoms can be clearly attributed to poorly controlled GOR.Entities:
Keywords: Asthma; GORD; PPI; cough; surgery
Year: 2013 PMID: 24917938 PMCID: PMC4040779 DOI: 10.1177/2050640612473964
Source DB: PubMed Journal: United European Gastroenterol J ISSN: 2050-6406 Impact factor: 4.623